1-6 of 6
James L. Speyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine

Free
Ruth Oratz, Margaret Dugan, Daniel F. Roses, Matthew N. Harris, James L. Speyer, Howard Hochster, Jolie Weissman, Mila Henn, Jean-Claude Bystryn
Journal: Cancer Research
Cancer Res (1991) 51 (14): 3643–3647.
Published: 01 July 1991
View articletitled, Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine
Open the PDF for Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine in another window
Journal Articles

Plasma Pharmacokinetics of Adriamycin and Adriamycinol: Implications for the Design of in Vitro Experiments and Treatment Protocols

Free
Raymond F. Greene, Jerry M. Collins, Jean F. Jenkins, James L. Speyer, Charles E. Myers
Journal: Cancer Research
Cancer Res (1983) 43 (7): 3417–3421.
Published: 01 July 1983
View articletitled, Plasma Pharmacokinetics of Adriamycin and Adriamycinol: Implications for the Design of in Vitro Experiments and Treatment Protocols
Open the PDF for Plasma Pharmacokinetics of Adriamycin and Adriamycinol: Implications for the Design of in Vitro Experiments and Treatment Protocols in another window
Journal Articles

Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer

Free
Robert F. Ozols, Robert C. Young, James L. Speyer, Paul H. Sugarbaker, Raymond Greene, Jean Jenkins, Charles E. Myers
Journal: Cancer Research
Cancer Res (1982) 42 (10): 4265–4269.
Published: 01 October 1982
View articletitled, Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer
Open the PDF for Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer in another window
Journal Articles

Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule

Free
Robert J. Spiegel, Ronald H. Blum, Mark Levin, Carolina A. Pinto, James C. Wernz, James L. Speyer, Kim S. Hoffman, Franco M. Muggia
Journal: Cancer Research
Cancer Res (1982) 42 (1): 354–358.
Published: 01 January 1982
View articletitled, Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule
Open the PDF for Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule in another window
Journal Articles

Portal Levels and Hepatic Clearance of 5-Fluorouracil after Intraperitoneal Administration in Humans

Free
James L. Speyer, Paul H. Sugarbaker, Jerry M. Collins, Robert L. Dedrick, Raymond W. Klecker, Jr., Charles E. Myers
Journal: Cancer Research
Cancer Res (1981) 41 (5): 1916–1922.
Published: 01 May 1981
View articletitled, Portal Levels and Hepatic Clearance of 5-Fluorouracil after Intraperitoneal Administration in Humans
Open the PDF for Portal Levels and Hepatic Clearance of 5-Fluorouracil after Intraperitoneal Administration in Humans in another window
Journal Articles

Phase I and Pharmacological Studies of 5-Fluorouracil Administered Intraperitoneally

Free
James L. Speyer, Jerry M. Collins, Robert L. Dedrick, Murray F. Brennan, Alan R. Buckpitt, Harold Londer, Vincent T. DeVita, Jr., Charles E. Myers
Journal: Cancer Research
Cancer Res (1980) 40 (3): 567–572.
Published: 01 March 1980
View articletitled, Phase I and Pharmacological Studies of 5-Fluorouracil Administered Intraperitoneally
Open the PDF for Phase I and Pharmacological Studies of 5-Fluorouracil Administered Intraperitoneally in another window